Five years after PACIFIC: Update on multimodal treatment efficacy based on real-world reports.
Farkhad ManapovAlexander NietoLukas KäsmannJulian TaugnerSaskia KenndoffBenedikt FlörschJulian GuggenbergerKerstin HofstetterSophie KröningerJanina LehmannHelene KravutskeCarolyn PelikanClaus BelkaChukwuka EzePublished in: Expert opinion on investigational drugs (2023)
The obvious question posed in this context of a very heterogeneous inoperable stage III NSCLC disease is: How can we augment an ability to predict checkpoint inhibition success or failure? Which tools and biomarkers, which clinical metadata and genetic background are relevant and feasible? No single biomarker will ever fully dominate the unresectable stage III NSCLC space, so we advocate multilevel and multivariate analysis of biomarkers. In this particular opinion piece, we explore the impact of PD-L1 expression on tumor cells, neutrophil-to-lymphocyte ratio, EGFR and STK11 mutational status, interferon-gamma signature, and tumor-infiltrating lymphocytes among others.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- locally advanced
- epidermal growth factor receptor
- dna damage
- brain metastases
- cell cycle
- tyrosine kinase
- pain management
- peripheral blood
- emergency department
- squamous cell carcinoma
- data analysis
- oxidative stress
- combination therapy
- cell proliferation
- adverse drug
- dna methylation
- chronic pain
- replacement therapy
- liver metastases
- electronic health record